M42 and Broad Institute work together with Microsoft and the International Center for Genetic Disease leveraging Terra to enable a foundation for precision health

• This work sets the foundation for the transformation of clinico-genomic data access, data science and international genomic research.
• This is a first step toward deploying a scalable data platform and analytical capabilities to support precision medicine and life science strategies in the UAE and globally.
• Terra will also serve as the foundation for M42’s Global Life Sciences Platform to unlock a new generation of omics-powered clinical trials.

Dubai, UAE: 30 January 2024: M42 — a first-of-its-kind health powerhouse committed to reshaping the sustainable future of health with technology as a key enabler — and Broad Institute of MIT and Harvard will work with Microsoft and the International Center for Genetic Disease. The group will leverage the Terra platform to explore scenarios for precision health discovery and delivery, collaborating with healthcare organizations across the global ecosystem. Terra, which will be deployed on the UAE cloud with sovereign capabilities powered by Microsoft Azure, will be used not only as a Trusted Research Environment, but also as the foundation for M42’s Global Life Sciences Platform.